Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xalkori Development Timeline

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

A chronology of significant events in the regulatory review process for Pfizer’s oncologic.

You may also be interested in...



Xarelto And Eylea Keep Bayer Buoyant

The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.

Holland & Barrett Pulls Irish CBD Products Following Safety Concerns

Holland & Barrett's Jacob Hooy brand is one of 15 CBD products recalled by the Irish food authority due to higher than stated doses of THC. 

BioMarin All Set For Hemophilia Gene Therapy Approval, But Is It Overestimating Demand?

Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.

Topics

UsernamePublicRestriction

Register

PS005041

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel